Foghorn Therapeutics (FHTX) Interest Expenses (2019 - 2026)

Foghorn Therapeutics' Interest Expenses history runs 8 years deep, the most recent figure standing at $60.8 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 2101.7% year-over-year to $60.8 million in Q1 2026; TTM through Mar 2026 was $60.8 million, a 293.8% increase from a year earlier, with the FY2025 full-year figure at $187.6 million, up 12.74% from the prior year.
• Interest Expenses improved to $60.8 million in Q1 2026 per FHTX's latest filing, from $1.7 million in the prior quarter.
• Across five years, Interest Expenses topped out at $143.0 million in Q4 2023 and bottomed at $25000.0 in Q3 2024.
• The 5-year median for Interest Expenses is $2.7 million (2023), against an average of $21.1 million.
• Across the five-year window, Interest Expenses tumbled 98.68% in 2024 and surged 101028.0% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $10.0 million in 2022, then soared by 1331.67% to $143.0 million in 2023, then sank by 98.12% to $2.7 million in 2024, then plunged by 37.53% to $1.7 million in 2025, then surged by 3513.25% to $60.8 million in 2026.
• Per Business Quant, the three latest FHTX Interest Expenses figures stand at $60.8 million (Q1 2026), $1.7 million (Q4 2025), and $25.3 million (Q3 2025).